What are the major challenges for CAR T-cell therapies in Europe during the COVID-19 pandemic?

During the Virtual 47th Annual Meeting of the European Society for Blood and Marrow Transplantation...

NCCN COVID-19 vaccination recommendations for patients with hematologic malignancies

Patients with cancer are at high risk of COVID-19-associated complications and, accordingly, the preliminary...

Lymphoma and COVID-19: Management guidelines

Throughout the COVID-19 pandemic, healthcare has faced a myriad of challenges, including restrictions on cancer therapies and other medical resources.

FDA delays decision on lisocabtagene maraleucel for adult patients with large B-cell lymphoma

The U.S. Food and Drug Administration (FDA) has announced that it will not meet the Prescription Drug User...

What are the major challenges for CAR T-cell therapies in Europe during the COVID-19 pandemic?

During the Virtual 47th Annual Meeting of the European Society for Blood and Marrow Transplantation...

Updated results from ZUMA-2 trial investigating KTE-X19 in R/R mantle cell lymphoma

During the 47th Annual Meeting of the European Society of Blood and Marrow Transplantation (EBMT), investigators...

ZUMA 2: How does prior BTK inhibitor treatment affect the efficacy of KTE-X19 in patients with MCL?

During the Virtual 47th Annual Meeting of the European Society for Blood and Marrow Transplantation...

ZUMA-1 4-year follow-up: Polyclonal B-cell recovery and survival outcomes with axi-cel in R/R large B-cell lymphoma

Axicabtagene ciloleucel (axi-cel) is an autologous anti-CD19 chimeric antigen...

What are the major challenges for CAR T-cell therapies in Europe during the COVID-19 pandemic?

During the Virtual 47th Annual Meeting of the European Society for Blood and Marrow Transplantation...

Updated results from ZUMA-2 trial investigating KTE-X19 in R/R mantle cell lymphoma

During the 47th Annual Meeting of the European Society of Blood and Marrow Transplantation (EBMT), investigators...

ZUMA 2: How does prior BTK inhibitor treatment affect the efficacy of KTE-X19 in patients with MCL?

During the Virtual 47th Annual Meeting of the European Society for Blood and Marrow Transplantation...

ZUMA-1 4-year follow-up: Polyclonal B-cell recovery and survival outcomes with axi-cel in R/R large B-cell lymphoma

Axicabtagene ciloleucel (axi-cel) is an autologous anti-CD19 chimeric antigen...